Novavax (NASDAQ:NVAX) Stock Price Breaks Above 50-Day Moving Average – Here’s Why

Shares of Novavax, Inc. (NASDAQ:NVAX) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $10.56 and traded as high as $10.93. Novavax shares last traded at $10.78, with a volume of 6,284,977 shares.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NVAX. Cantor Fitzgerald reissued an “overweight” rating on shares of Novavax in a research note on Tuesday, October 27th. Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Wall Street Zen raised Novavax from a “hold” rating to a “buy” rating in a report on Saturday. B. Riley Financial reaffirmed a “buy” rating and issued a $16.00 price target (down from $18.00) on shares of Novavax in a report on Friday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a report on Monday. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $12.33.

Novavax Stock Performance

The stock’s fifty day simple moving average is $10.56 and its two-hundred day simple moving average is $9.35. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -23.43 and a beta of 2.65.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.16. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The company had revenue of $68.30 million during the quarter, compared to analyst estimates of $50.42 million. During the same period in the previous year, the company earned ($1.25) earnings per share. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. Analysts predict that Novavax, Inc. will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Novavax

Several hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in shares of Novavax in the second quarter valued at about $8,004,000. Squarepoint Ops LLC bought a new position in Novavax during the second quarter worth about $1,258,000. Renaissance Technologies LLC acquired a new position in Novavax in the 1st quarter worth about $4,049,000. Edgestream Partners L.P. purchased a new position in shares of Novavax in the 1st quarter worth approximately $4,234,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Novavax in the 2nd quarter worth approximately $739,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

About Novavax

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.